APA (7th ed.) Citation

H, T., T, E., S, O., T, F., N, T., N, T., . . . M, T. (2023). Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck. Frontiers in oncology, 13, 1221352. https://doi.org/10.3389/fonc.2023.1221352

Chicago Style (17th ed.) Citation

H, Tanaka, et al. "Subsequent Chemotherapy with Paclitaxel Plus Cetuximab-based Chemotherapy Following Immune Checkpoint Inhibitor in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck." Frontiers in Oncology 13 (2023): 1221352. https://doi.org/10.3389/fonc.2023.1221352.

MLA (9th ed.) Citation

H, Tanaka, et al. "Subsequent Chemotherapy with Paclitaxel Plus Cetuximab-based Chemotherapy Following Immune Checkpoint Inhibitor in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck." Frontiers in Oncology, vol. 13, 2023, p. 1221352, https://doi.org/10.3389/fonc.2023.1221352.